Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sanofi/Regeneron’s PSCK9 Inhibitor Alirocumab Passes First Phase III Test

Oct 17 2013

• By Emily Hayes

Related Content

Momentum Builds For PCSK9 Class, But Proof Of Safety Still Thin

Nov 12 2012

Seeing Dollar Signs In Statin Intolerance

Apr 23 2012

The Medicines Co. Enters PCSK9 Race With Alnylam Deal

Feb 04 2013

Panel To Weigh Amarin’s Expanded <em>Vascepa</em> Use Given Clinical Outcome Concerns

Oct 11 2013

Related Companies

Sanofi

Regeneron Pharmaceuticals, Inc.

Merck & Co., Inc.

Amgen, Inc.

Astria Therapeutics, Inc.

The Medicines Company

Alnylam Pharmaceuticals Inc.

Amarin Corp plc

Additional Topics

Clinical Trials Research & Development

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window